Dr. Forsberg received his bachelor’s degree from Washington University in St. Louis. He completed medical school at the University of Colorado School of Medicine. He went to New York for his medical training and completed his residency in Internal Medicine at the Weill-Cornell Medical College/New York-Presbyterian Hospital. He served as chief medical resident at Memorial Sloan Kettering Cancer Center before returning to Cornell for his fellowship training in Hematology and Medical Oncology. In 2016 he returned to Colorado to join the blood cancer and BMT program at the University of Colorado.

Dr. Forsberg’s clinical and research focus centers on multiple myeloma and related diseases including amyloidosis and Waldenstrom’s Macroglobulinemia. He serves as the principle investigator on various clinical trials. He has published and presented his work at the national and international level.

Locations

Monday: 8am - 4:30pm
Tuesday: 8am - 4:30pm
Wednesday: 8am - 4:30pm
Thursday: 8am - 4:30pm
Friday: 8am - 4:30pm
Saturday: Closed
Sunday: Closed

Qualifications and experience

Specialties
Internal Medicine, Hematology and Oncology
Gender
Male
Education
Fellowship
New York Presbyterian Hospital (Cornell Campus) Program (2016)

Medical School
University of Colorado Denver School of Medicine (2009)

Residency
Memorial Sloan-Kettering Cancer Center Program (2013)

Residency
New York Presbyterian Hospital (Cornell Campus) Program (2012)

Undergraduate
Washington University in Saint Louis (MO) (2004)

Research interest for patients

Dr. Forsberg’s research is focused on developing novel strategies to treat plasma cell disorders including multiple myeloma. He works in collaboration with a group of clinical and laboratory based researchers to better characterize the biology of plasma cell diseases, understand the heterogeneity of these disorders in individual patients and develop personalized approaches to therapy in myeloma and related diseases.

He is working to identify new therapeutic targets in multiple myeloma and to identify biomarkers to predict patient responses to different treatments. He is also interested in evaluating and finding approaches to improve the quality of life in patients dealing with a group of diseases whose therapeutic landscape has evolved rapidly in the past several years.

Region
None